Omada Health, Inc.
For the period ended Sep 30, 2025. Filed Nov 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities | ||
| Net loss | $(17,937) | $(38,887) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Depreciation and amortization | 4,044 | 3,525 |
| Share-based compensation | 9,210 | 7,108 |
| Loss on debt extinguishment | 2,109 | - |
| Loss on disposal of property and equipment | 2 | 2 |
| Amortization of debt issuance costs | 285 | 291 |
| Non-cash operating lease expense | 447 | 541 |
| Change in fair value of warrants | 1,468 | (445) |
| Provision for credit losses (1) | 1,485 | 751 |
| Amortization of deferred commissions | 2,467 | 1,901 |
| Changes in operating assets and liabilities | - | - |
| Accounts receivable (2) | (19,514) | (9,676) |
| Inventory | 148 | 1,845 |
| Prepaid expenses and other current assets | (1,570) | (656) |
| Deferred commissions | (2,319) | (4,872) |
| Other non-current assets | 181 | 331 |
| Accounts payable | 1,373 | 1,488 |
| Operating lease liabilities | (415) | (581) |
| Accrued expenses and other current liabilities (3) | 7,782 | 1,682 |
| Deferred revenue (4) | 7,627 | 7,825 |
| Other non-current liabilities | - | 135 |
| Net cash used in operating activities | (3,127) | (27,692) |
| Investing activities | ||
| Purchases of property and equipment | (1,123) | (412) |
| Capitalized internal-use software costs | (3,363) | (2,482) |
| Net cash used in investing activities | (4,486) | (2,894) |
| Financing activities | ||
| Proceeds from exercise of stock options | 5,993 | 2,045 |
| Payment of deferred offering costs | (4,284) | (3,367) |
| Repayment of debt principal | (30,963) | - |
| Payment of debt extinguishment costs | (1,430) | - |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 160,532 | - |
| Net cash provided by (used in) financing activities | 129,848 | (1,322) |
| Net increase (decrease) in cash and cash equivalents | 122,235 | (31,908) |
| Cash and cash equivalents at beginning of period | 76,392 | 115,643 |
| Cash and cash equivalents at end of period | $198,627 | $83,735 |
(1)Includes changes in related party balances of $0.5 million and $0.1 million for the nine months ended September 30, 2025 and 2024, respectively.
(2)Includes changes in related party balances of $15.6 million and $6.5 million for the nine months ended September 30, 2025 and 2024, respectively.
(3)Includes changes in related party balances of $3.0 million and $0.8 million for the nine months ended September 30, 2025 and 2024, respectively.
(4)Includes changes in related party balances of $7.1 million and $5.7 million for the nine months ended September 30, 2025 and 2024, respectively.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Supplemental disclosure of cash flow information | ||
| Cash paid during the period for: | ||
| Interest | $2,420 | $2,921 |
| Supplemental disclosure of noncash investing and financing activities | ||
| Share-based compensation expense capitalized in internal-use software | $129 | $74 |
| Unpaid deferred offering costs included in accounts payable | - | 822 |
| Unpaid property and equipment included in accounts payable | - | 16 |
| Net share settlement of redeemable convertible preferred stock warrant liability in connection with Series B redeemable convertible preferred stock warrant exercise | 493 | - |
| Net share settlement of redeemable convertible preferred stock warrant liability in connection with Series D redeemable convertible preferred stock warrant exercise | 3,227 | - |
| Net share settlement of common stock warrant liability | 647 | - |
| Conversion of redeemable convertible preferred stock in connection with initial public offering | 452,113 | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.